Effectiveness of the RISE Intervention
Launched by UMC UTRECHT · Nov 8, 2023
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called the RISE Intervention, is studying how effective a special program is in helping people who have had their first stroke to lead a healthier lifestyle and prevent serious heart-related problems, like another stroke or heart attack, over the course of a year. The trial involves 376 participants receiving the RISE program along with regular care, while another 376 participants will receive only the usual care. The goal is to see if the RISE program can help participants move more and sit less after they leave the hospital.
To take part in this study, individuals must be 18 years or older, have experienced a first stroke within the last six months, and be able to walk independently, even if they use a walking aid. Participants will be randomly assigned to either the RISE program or the usual care group. Throughout the study, participants will be asked to complete assessments at different times to track their progress. This trial is currently recruiting and aims to include a total of around 1,000 patients to ensure enough data is collected, even if some participants drop out.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- In order to be eligible to participate in the baseline measurement of the intervention study, a subject must meet all of the following criteria:
- • 1. Aged 18 years or older;
- • 2. All types of first-ever stroke diagnosed in hospital within six months before start of the RISE intervention;
- • 3. Able to walk independently, as defined by a Functional ambulation categories score of at least 3;
- • 4. Independent regarding activities of daily living pre-stroke, as defined by a Barthel Index score of \>18;
- • 5. Discharged to the home-setting;
- • 6. Not participating in a physical rehabilitation program lasting ≥ 3 months;
- • 7. Given their written informed consent.
- Exclusion Criteria:
- A potential subject will be excluded from participation in this study if:
- • 1. The participant has insufficient knowledge or is cognitively unable to understand the Dutch language of the intervention content;
- • 2. The participant has severe comorbidities that withhold that person from safely reducing and interrupting their sedentary time (e.g. sever pulmonary diseases, hart failure or malignity's) as determined with the Physical Activity Readiness Questionnaire;
About Umc Utrecht
UMC Utrecht is a leading academic medical center in the Netherlands, renowned for its commitment to innovative research and high-quality patient care. As a prominent sponsor of clinical trials, UMC Utrecht leverages its extensive expertise in translational medicine and collaboration with various stakeholders to advance medical knowledge and improve therapeutic outcomes. The institution emphasizes ethical conduct and rigorous scientific standards, ensuring that all research activities contribute meaningfully to the global healthcare landscape. Through its robust clinical trial infrastructure, UMC Utrecht plays a vital role in facilitating the development of new treatments and enhancing patient wellbeing.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vught, Brabant, Netherlands
'S Hertogenbosch, Noord Brabant, Netherlands
Eersel, Noord Brabant, Netherlands
Eindhoven, Noord Brabant, Netherlands
Eindhoven, Noord Brabant, Netherlands
Geldrop, Noord Brabant, Netherlands
Helmond, Noord Brabant, Netherlands
Helmond, Noord Brabant, Netherlands
Rosmalen, Noord Brabant, Netherlands
Valkenswaard, Noord Brabant, Netherlands
Vlijmen, Noord Brabant, Netherlands
Vught, Noord Brabant, Netherlands
Breukelen, Utrecht, Netherlands
Houten, Utrecht, Netherlands
Ijsselstein, Utrecht, Netherlands
Mijdrecht, Utrecht, Netherlands
Veenendaal, Utrecht, Netherlands
Wijk Bij Duurstede, Utrecht, Netherlands
Woerden, Utrecht, Netherlands
Zeist, Utrecht, Netherlands
Utrecht, , Netherlands
Patients applied
Trial Officials
Martijn F Pisters, Dr.
Principal Investigator
UMC Utrecht Brain Center and Fontys University of Applied Sciences
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported